BTIG Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Thomas Shrader has initiated coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and set a price target of $11.

December 21, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG initiated coverage on Ovid Therapeutics with a Buy rating and a price target of $11, which could positively influence the stock's performance.
Analyst ratings, especially from reputable firms like BTIG, can significantly impact a stock's short-term performance. A Buy rating combined with a price target that suggests substantial upside from the current trading price is likely to be viewed positively by investors, potentially driving up the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100